Metropolis Healthcare a diagnostic service firm enters the public domain by filling its IPO (Initial Public Offering). It is the third diagnostic company in India to make a market debut. It will be open on April 5th 2015.
Each share of Rs 2 face value of the company is priced in a band of the Rs 877-Rs 880. Investor can buy a lot size of 17 shares or more. It is listed on BSE and NSE.
Metropolis Healthcare broad range of approximately 3,480 clinical laboratory tests and 524 profiles and the laboratory network consists of 106 clinical laboratories and our service network comprises 1,130 patient touch points. Company has 4,585 full-time employees, including 183 pathologists and doctors and 2,022 scientific officers and phlebotomists located in India, and 222 full-time employees located outside India. It is present in 18 states and 173 cities and conducted 16 million tests and 7.7 million patients visited its labs as per FY18.
It is a debt free company. In the past three years, its net sales and net profit each has grown at a CAGR of 16 per cent to Rs 643.5 crore and Rs 88.7 crore, respectively, in FY18. Its operating profit margin was 27 per cent in FY18. Its revenue per test has steadily risen from Rs 354 in FY16 to Rs 454 for the nine months ended December 2019, and its revenues per patient have expanded from Rs 689 to Rs 847.
The Metropolis IPO valuations is of 37 times the estimated earnings of FY19. At a market cap of Rs 4,500 crore, the company is being valued at six times its annualised sales of FY19.